Catalog No.
DHC90701
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
B-lymphocyte surface antigen B1, Membrane-spanning 4-domains subfamily A member 1, MS4A1, Leukocyte surface antigen Leu-16, B-lymphocyte antigen CD20, Bp35, CD20
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P11836
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
HuMax-CD20-, CAS: 679818-59-8
Clone ID
Ofatumumab
Ofatumumab versus Teriflunomide in Multiple Sclerosis, PMID: 32757523
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study, PMID: 29695594
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia, PMID: 24881631
Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab, PMID: 33092190
Ofatumumab, PMID: 33091123
Ofatumumab, PMID: 26648645
Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis, PMID: 33090003
Ofatumumab, PMID: 31643960
Ofatumumab, PMID: 20481657
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL, PMID: 30287523
Ofatumumab, PMID: 20068404
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab, PMID: 30842083
Ofatumumab, PMID: 29999646
Ofatumumab (Kesimpta) for multiple sclerosis, PMID: 33451176
The use of ofatumumab in the treatment of B-cell malignancies, PMID: 28850252
Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study, PMID: 24453078
More on Ofatumumab for TTP, PMID: 29619817
More on Ofatumumab for TTP, PMID: 29617588
Ofatumumab, PMID: 20118960
Ofatumumab treatment for nephrotic syndrome recurrence after pediatric renal transplantation, PMID: 32306087
Ofatumumab for post-transplant lymphoproliferative disorder, PMID: 32413419
Ofatumumab in the treatment of non-Hodgkin's lymphomas, PMID: 26043777
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study, PMID: 28029326
Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial, PMID: 32589978
Safety and efficacy of Ofatumumab in chronic lymphocytic leukemia: a systematic review and meta-analysis, PMID: 28580841
Ofatumumab in the treatment of chronic lymphocytic leukemia, PMID: 20683500
Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia, PMID: 32855756
Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia, PMID: 21342032
Ofatumumab for the treatment of chronic lymphocytic leukemia, PMID: 25882470
Ofatumumab (Arzerra) for CLL, PMID: 20585286
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma, PMID: 31512258
Adult Acute Lymphoblastic Leukemia, PMID: 27814839
Ofatumumab, a human anti-CD20 monoclonal antibody, PMID: 20109133
Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia, PMID: 21896924
Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models, PMID: 23873847
Ofatumumab for treating chronic lymphocytic leukemia: a safety profile, PMID: 26566719
Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK, PMID: 21609654
Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia, PMID: 24947256
Ofatumumab - a valid treatment option for chronic lymphocytic leukemia patients, PMID: 28790834
Management of Waldenström macroglobulinemia in 2020, PMID: 33275726
Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?, PMID: 32619884
Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness, PMID: 31980477
Refractory pemphigus vulgaris successfully treated with ofatumumab, PMID: 32715065
Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia, PMID: 21030349
Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies, PMID: 22830942
Ofatumumab in the treatment of low-grade non-Hodgkin's lymphomas and chronic lymphocytic leukemia, PMID: 21595596
New developments in the management of chronic lymphocytic leukemia: role of ofatumumab, PMID: 26855591
Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study, PMID: 31801940
Ofatumumab use in juvenile systemic lupus erythematosus: A single centre experience, PMID: 33327846
Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies, PMID: 20458041
For research use only. Not for human or drug use.
